We are excited to share that our Early Phase Unit in Manchester dosed the first participant in Small Pharma’s first-in-human Phase I clinical trial of their proprietary deuterated candidate. This clinical development program will explore whether an extended duration could offer a treatment tailored for other mental health conditions in addition to depression. Additionally, the pharmacokinetic profile of SPL028 offers the opportunity to explore additional routes of administration, potentially expanding patient convenience.
It is an honour to be a part of such ground-breaking clinical research. One of MAC’s in-house psychiatrists, Dr. David Gregory, was present with the participant at this first dosing and noted “to commence any new research is always truly fascinating and being a part of this special program that holds such promise to revolutionise mental health is hugely exciting”.
The full press release is available here.
MAC offer full clinical trial support for the administration of psychedelic-assisted therapies. With our patient-centric approach, we ensure the participants feel relaxed and at home during their experience. Said one patient recently: “They make an environment at the psychedelic ward which was always open, calming, and warm.”
Do download our information sheet to learn more about our experts and bespoke facilities.